CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
Miricorilant +1 moredrug
Likely dose
Miricorilant 900 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04466215
NCT04466215Phase 2Completed
CompareCT.gov

Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo

The Scripps Research Institute·interventional·Posted Jul 10, 2020·Updated Feb 3, 2023

In Brief

A Phase 2 clinical trial evaluating Miricorilant and Placebo oral tablet for Alcohol Use Disorder. Completed, enrolled 50 participants across 1 site.

Detailed Summary

The hypotheses under test are that subjects with alcohol use disorder (AUD) of moderate or greater severity treated with CORT118335 will report decreased craving for alcohol following alcohol exposure in the laboratory and report significantly less drinking under naturalistic conditions, than those treated with placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Use Disorder
CountriesUnited States
CollaboratorsNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJul 10, 2020
Enrollment StartApr 15, 2021
Primary CompletionApr 15, 2022
Study CompletionJun 7, 2022
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 6.0 years ago

Interventions

Miricorilantdrug

900 mg (6 x 150 mg) tablets taken orally once daily for two weeks

Placebo oral tabletdrug

Six placebo tablets taken orally once daily for two weeks